Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial

The Lancet Oncology

Volumn 16, Issue 9, 2015, Pages 1037-1048

  Bear, Harry D ^a,b   Tang, Gong ^c   Rastogi, Priya ^a,d   Geyer, Charles E ^a,b   Liu, Qing ^c   Robidoux, André ^a,e   Baez Diaz, Luis ^a,f   Brufsky, Adam M ^a,d   Mehta, Rita S ^a,g   Fehrenbacher, Louis ^a,h   Young, James A ^a,i   Senecal, Francis M ^a,j   Gaur, Rakesh ^a,k   Margolese, Richard G ^a,l   Adams, Paul T ^a,m   Gross, Howard M ^a,n   Costantino, Joseph P ^c   Paik, Soonmyung ^a,o   Swain, Sandra M ^a,p   Mamounas, Eleftherios P ^a,q   Wolmark, Norman ^a,r   more..

^a NSABP Foundation Inc   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Minority Based CCOP San Juan   (Puerto Rico)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ Colorado Springs ^*  (United States)

^j Northwest Medical Specialties   (United States)

^k CCOP   (United States)

^l MCGILL UNIVERSITY   (Canada)

^m GENESYS REGIONAL MEDICAL CENTER   (United States)

ⁿ CCOP   (United States)

^o Yonsei University College of Medicine   (South Korea)

^p WASHINGTON CANCER INSTITUTE   (United States)

^q UNIVERSITY OF FLORIDA   (United States)

^r ALLEGHENY GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; DEOXYCYTIDINE; TAXOID;

ADULT; ADVERSE OUTCOME; ARTICLE; BACTERIAL ENDOCARDITIS; BONE PAIN; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CAUSE OF DEATH; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EARLY CANCER; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEEDLE BIOPSY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; SENSORY NEUROPATHY; SUDDEN DEATH; THROMBOSIS; THROMBUS; TUMOR INVASION; TUMOR VOLUME; VOMITING; WOUND INFECTION; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; BEVACIZUMAB; BREAST NEOPLASMS; CAPECITABINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TAXOIDS; UNITED STATES;

EID: 84940606731     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00041-8     Document Type: Article

References (53)

1. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
2. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
4. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009, 27:2474-2481.
5. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27. J Clin Oncol 2003, 21:4165-4174.
6. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from the escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
7. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696.
8. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24:5664-5671.
9. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
10. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14:1317-1325.
11. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
12. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
13. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014, 384:164-172.
14. Prowell TM, Pazdur R Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012, 366:2438-2441.
15. Guidance for Industry. Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval US Food and Drug Administration, (accessed May 13, 2015). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf.
16. Folkman J, Merler E, Abernathy C, Williams G Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133:275-288.
17. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
18. Weidner N, Semple JP, Welch WR, Folkman J Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
19. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1887.
20. Holmgren L, O'Reilly MS, Folkman J Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153.
21. O'Reilly MS, Holmgren L, Chen C, Folkman J Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996, 2:689-692.
22. O'Reilly MS Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 1997, 79:273-294.
23. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
24. Ellis LM, Fidler IJ Angiogenesis and breast cancer metastasis. Lancet 1995, 346:388-390.
25. Prehn RT The inhibition of tumor growth by tumor mass. Cancer Res 1991, 51:2-4.
26. Kim KJ, Li B, Winer J, Armanini M, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
27. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
28. Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K Bevacizumab and breast cancer: what does the future hold?. Future Oncol 2012, 8:403-414.
29. Kümler I, Christiansen OG, Nielsen DL A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 2014, 40:960-973.
30. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309.
31. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
32. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
33. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
34. Miller K, O'Neill AM, Dang CT, et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 2014, 32:500.
35. Slamon DJ, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. Cancer Res 2013, 73:S01-S03.
36. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013, 14:933-942.
37. White SJ, Freedman LS Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978, 37:849-857.
38. Turnbull BW, Jennison C Group sequential methods with application to clinical trials 2000, Chapman & Hall, Boca Raton, FL.
39. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
40. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
41. Cox DR Regression models and life tables (with discussion). J R Stat Soc Ser B Stat Meth 1972, 30:248-275.
42. O'Quigley J Proportional Hazards Regression (Statistics for Biology and Health) 2008, Springer, New York. 1st edn.
43. Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013, 24:2978-2984.
44. von Minckwitz G, Loibl S, Untch M, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). Ann Oncol 2014, 25:2363-2372.
45. Nahleh ZA, Barlow WE, Hayes DF, et al. S0800: nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131). Cancer Res 2015, 75:P3-11. 16.
46. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Res 2013, 73:S5. 01.
47. Earl HM, Hiller L, Dunn JA, et al. ARTemis: a randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer. San Antonio Breast Cancer Symposium; San Antonio; Dec 9-14, 2014. Abstr PD2-3.
48. Kerbel RS Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
49. Bagri A, Kouros-Mehr H, Leong KG, Plowman GD Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol Med 2010, 16:122-132.
50. Mountzios G, Pentheroudakis G, Carmeliet P Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 2014, 141:117-124.
51. Carmeliet P, Jain RK Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427.
52. Bellou S, Pentheroudakis G, Murphy C, Fotsis T Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett 2013, 338:219-228.
53. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.